| Other Names | Eltanexor, KPT-8602, 1642300-52-4, (E)-3-(3-(3, 5-Bis(trifluoromethyl)phenyl)-1H-1, 2, 4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide, Eltanexor [INN], Eltanexor [USAN], Eltanexor [WHO-DD], KPT8602, Q59IQJ9NTK, (E)-3-[3-[3, 5-bis(trifluoromethyl)phenyl]-1, 2, 4-triazol-1-yl]-2-pyrimidin-5-ylprop-2-enamide, (2E)-3-{3-[3, 5-bis(trifluoromethyl)phenyl]-1H-1, 2, 4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enamide, eltanexorum, (2E)-3-(3-(3, 5-Bis(trifluoromethyl)phenyl)-1H-1, 2, 4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide, (E)-3-(3-(3, 5-bis(trifluoromethyl)phenyl)-1, 2, 4-triazol-1-yl)-2-pyrimidin-5-ylprop-2-enamide, Eltanexor (USAN/INN), UNII-Q59IQJ9NTK, Eltanexor(KPT-8602), KPT-8602 Eltanexor, Eltanexor (KPT-8602), CHEMBL4297623, SCHEMBL16324809, C17H10F6N6O, GTPL10037, ATG-016, Eltanexor [USAN:INN:WHO-DD], CHEBI:229762, JFBAVWVBLRIWHM-AWNIVKPZSA-N, GLXC-10710, EX-A2433, KPT 8602, ONO-7706, SQC30052, NSC794443, s8397, WHO 10496, AKOS032945053, CCG-268977, CS-5947, NSC-794443, AC-36070, BS-15585, DA-74785, HY-100423, C73170, D11499, 5-PYRIMIDINEACETAMIDE, .ALPHA.-((3-(3, 5-BIS(TRIFLUOROMETHYL)PHENYL)-1H-1, 2, 4-TRIAZOL-1-YL)METHYLENE)-, (.ALPHA.E)-, 5-Pyrimidineacetamide, alpha-((3-(3, 5-bis(trifluoromethyl)phenyl)-1H-1, 2, 4-triazol-1-yl)methylene)-, (alphaE)- |
|---|---|
| IUPAC Name | tert-butyl N-(3-iodo-2H-pyrazolo[3, 4-d]pyrimidin-4-yl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate |
| CAS | 1491152-26-1 |
| Molecular Weight | 428.29 |
| Molecular Formula | C17H10F6N6O |
| SMILES | C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C2=NN(C=N2)C=C(C3=CN=CN=C3)C(=O)N |



![1H-Pyrrolo[2,3-b]pyridine, 3-bromo-4-chloro- - (1000340-39-5)](https://eontrading.uk/wp-content/uploads/2025/04/1000340-39-5.png)


